title: Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies.
abstract: BACKGROUND
  The serotonin and noradrenaline (norepinephrine) reuptake inhibitor duloxetine has been approved in the US and elsewhere for a number of indications, including psychiatric illnesses and chronic pain conditions. Because the patient populations are diverse within these approved indications, and duloxetine is not yet approved for treatment of other conditions, we wanted to determine if adverse event profiles would differ among patients being treated for these various conditions.
  
  
  OBJECTIVE
  To provide detailed information on the adverse events associated with duloxetine and to identify differences in the adverse event profile between treatment indications and patient demographic subgroups.
  
  
  METHODS
  Data were analysed from all placebo-controlled trials of duloxetine completed as of December 2008. The 52 studies included 17,822 patients (duloxetine n = 10,326; placebo n = 7496) with major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, osteoarthritis knee pain (OAKP), chronic lower back pain and lower urinary tract disorders. The main outcome measures were rates of treatment-emergent adverse events (TEAEs) and adverse events reported as the reason for discontinuation.
  
  
  RESULTS
  The overall TEAE rate was 57.2% for placebo-treated patients and 72.4% for duloxetine-treated patients (p < or = 0.001). Patients with OAKP had the lowest TEAE rate (placebo 36.7% vs duloxetine 50.2%, p < or = 0.01), while patients with fibromyalgia had the highest rate (placebo 80.0% vs duloxetine 89.0%, p < or = 0.001). The most common TEAE for all indications was nausea (placebo 7.2% vs duloxetine 23.4%, p < or = 0.001), which was predominantly mild to moderate in severity. No statistically significant treatment-by-subgroup interactions for age were found between placebo and duloxetine treatment for the most common TEAEs. The rates of duloxetine-associated dry mouth and fatigue were greater in women than in men (13.1% vs 10.4%, interaction p = 0.004; and 9.4% vs 7.6%, interaction p = 0.03, respectively). Duloxetine-associated dry mouth incidence was higher in Caucasians than non-Caucasians (13.2%, 11.0%, interaction p = 0.04).
  
  
  CONCLUSIONS
  Duloxetine treatment is associated with significantly higher rates of common TEAEs versus placebo, regardless of indication or demographic subgroup. Differences across indications are likely to be attributable to the underlying condition rather than duloxetine, as suggested by the similar trends observed in placebo- and duloxetine-treated patients.
authors.affiliation: Faculty Development, Cabarrus Family Medicine Residency, Concord, North Carolina, USA.
authors.forename: Stephen
authors.initials: S
authors.lastname: Brunton
authors.forename: Fujun
authors.initials: F
authors.lastname: Wang
authors.forename: S Beth
authors.initials: SB
authors.lastname: Edwards
authors.forename: Antonio S
authors.initials: AS
authors.lastname: Crucitti
authors.forename: Melissa J
authors.initials: MJ
authors.lastname: Ossanna
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Walker
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Robinson
mesh_terms: D000367:Age Factors; D000928:Antidepressive Agents / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D000068736:Duloxetine Hydrochloride; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D044469:Racial Groups; D016032:Randomized Controlled Trials as Topic; D012737:Sex Factors; D013876:Thiophenes / Q000009:adverse effects*
chemical_list: D000928:Antidepressive Agents; D013876:Thiophenes; D000068736:Duloxetine Hydrochloride
references.citation: Pain. 1999 Dec;83(3):389-400
references.pmid: 10568846
references.citation: Prog Neurobiol. 2002 Apr;66(6):355-474
references.pmid: 12034378
references.citation: Pain Med. 2005 Sep-Oct;6(5):346-56
references.pmid: 16266355
references.citation: Eur J Neurol. 2009 Sep;16(9):1041-8
references.pmid: 19469829
references.citation: J Clin Psychiatry. 2007 Nov;68(11):1707-16
references.pmid: 18052564
references.citation: Neurourol Urodyn. 2008;27(3):212-21
references.pmid: 17580357
references.citation: Int Urogynecol J Pelvic Floor Dysfunct. 2005 Sep-Oct;16(5):337-44
references.pmid: 15662490
references.citation: J Clin Psychiatry. 2006 Sep;67(9):1379-90
references.pmid: 17017824
references.citation: Prog Brain Res. 1991;88:381-94
references.pmid: 1813927
references.citation: J Clin Psychiatry. 2007 Dec;68(12):1921-30
references.pmid: 18162024
references.citation: Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70
references.pmid: 15589385
references.citation: Arthritis Rheum. 2004 Sep;50(9):2974-84
references.pmid: 15457467
references.citation: Eur Psychiatry. 2006 Sep;21(6):367-78
references.pmid: 16697153
references.citation: BJU Int. 2004 Feb;93(3):311-8
references.pmid: 14764128
references.citation: J Affect Disord. 2006 Aug;94(1-3):183-9
references.pmid: 16780958
references.citation: Curr Med Res Opin. 2007 Feb;23(2):401-16
references.pmid: 17288694
references.citation: Obstet Gynecol. 2004 Sep;104(3):511-9
references.pmid: 15339761
references.citation: J Clin Psychopharmacol. 2004 Aug;24(4):389-99
references.pmid: 15232330
references.citation: BJU Int. 2007 Aug;100(2):337-45
references.pmid: 17511767
references.citation: Pain. 1995 Jan;60(1):91-102
references.pmid: 7715946
references.citation: Int J Gen Med. 2008 Nov 30;1:91-102
references.pmid: 20428412
references.citation: Psychol Med. 2009 Feb;39(2):267-76
references.pmid: 18485261
references.citation: Curr Med Res Opin. 2006 Nov;22(11):2121-9
references.pmid: 17076972
references.citation: Eur J Obstet Gynecol Reprod Biol. 2006 Mar 1;125(1):120-8
references.pmid: 16188367
references.citation: Psychopharmacol Bull. 2002 Autumn;36(4):106-32
references.pmid: 12858150
references.citation: Int J Neuropsychopharmacol. 2002 Dec;5(4):315-25
references.pmid: 12466031
references.citation: Pain. 2005 Jul;116(1-2):109-18
references.pmid: 15927394
references.citation: J Psychiatr Res. 2002 Nov-Dec;36(6):383-90
references.pmid: 12393307
references.citation: Prim Care Companion J Clin Psychiatry. 2007;9(2):100-7
references.pmid: 17607331
references.citation: Spine (Phila Pa 1976). 2010 Jun 1;35(13):E578-85
references.pmid: 20461028
references.citation: Neurology. 2006 Oct 24;67(8):1411-20
references.pmid: 17060567
references.citation: Int Urogynecol J Pelvic Floor Dysfunct. 2007 Aug;18(8):919-29
references.pmid: 17160693
references.citation: Am Fam Physician. 2007 Jul 15;76(2):247-54
references.pmid: 17695569
references.citation: Br J Clin Pharmacol. 2004 Jan;57(1):54-61
references.pmid: 14678340
references.citation: Prim Care Companion J Clin Psychiatry. 2004;6(2):65-73
references.pmid: 15254599
references.citation: Pain. 2009 Dec;146(3):253-260
references.pmid: 19625125
references.citation: Am J Obstet Gynecol. 2002 Jul;187(1):40-8
references.pmid: 12114886
references.citation: Psychiatry (Edgmont). 2007 Mar;4(3):39-45
references.pmid: 20805909
references.citation: BJOG. 2004 Mar;111(3):249-57
references.pmid: 14961887
references.citation: Pain. 2005 Dec 15;119(1-3):5-15
references.pmid: 16298061
references.citation: J Clin Psychiatry. 2002 Mar;63(3):225-31
references.pmid: 11926722
references.citation: Prog Drug Res. 2002;58:169-222
references.pmid: 12079200
references.citation: Hum Psychopharmacol. 2005 Jul;20(5):327-41
references.pmid: 15912562
references.citation: Curr Med Res Opin. 2007 Jan;23(1):175-84
references.pmid: 17257478
references.citation: J Clin Psychiatry. 2006;67 Suppl 6:3-8
references.pmid: 16848670
references.citation: Int Clin Psychopharmacol. 2005 Mar;20(2):59-69
references.pmid: 15729080
references.citation: BJOG. 2007 May;114(5):543-7
references.pmid: 17355360
references.citation: J Clin Psychiatry. 2002 Apr;63(4):308-15
references.pmid: 12000204
references.citation: BMC Urol. 2008 Jan 25;8:2
references.pmid: 18221532
references.citation: J Urol. 2003 Oct;170(4 Pt 1):1259-63
references.pmid: 14501737
references.citation: Pain. 2008 Jun;136(3):432-444
references.pmid: 18395345
references.citation: Pain Med. 2007 Sep;8(6):503-13
references.pmid: 17716324
references.citation: J Clin Psychopharmacol. 2008 Feb;28(1):32-8
references.pmid: 18204338
references.citation: Ann N Y Acad Sci. 1990;600:511-9; discussion 519-20
references.pmid: 2252330
references.citation: Depress Anxiety. 2008;25(3):182-9
references.pmid: 17311303
references.citation: Am J Psychiatry. 2007 Jun;164(6):900-9
references.pmid: 17541049
references.citation: Maturitas. 2008 Jun 20;60(2):138-47
references.pmid: 18547757
references.citation: Int Clin Psychopharmacol. 2007 May;22(3):167-74
references.pmid: 17414743
references.citation: J Psychiatr Res. 2005 Jan;39(1):43-53
references.pmid: 15504423
references.citation: Neuropsychopharmacology. 2001 Dec;25(6):871-80
references.pmid: 11750180
references.citation: J Urol. 2005 May;173(5):1647-53
references.pmid: 15821528